The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | iStopMM: a new, large & unbiased MGUS patient population
Sigrun Thorsteinsdottir, MD, National University Hospital of Iceland, Reykjavik, Iceland, outlines some of the benefits of the ongoing iStopMM study (NCT03327597). Dr Thorsteinsdottir explains that the study’s cohort will enable us to better understand the biology of myeloma precursor diseases. Indeed, in contrast to previous monoclonal gammopathy of undetermined significance (MGUS) cohorts where patients were clinically diagnosed with MGUS and had several other comorbidities, this cohort is unbiased. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
